Patents
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
03/2007
03/14/2007CN1927400A Biomagnetism nano target anti-cancer drug and its preparation
03/14/2007CN1927399A Application of non-nucleoside virus reverse transcriptase inhibiting compound and derivative thereof for anti-hepatitis B virus purpose
03/14/2007CN1927398A Medicinal composition comprising active components of 5-HT 3 receptor antagonist and H2 receptor antagonist and use thereof
03/14/2007CN1927393A Composite collagen gel
03/14/2007CN1927392A Composite collagen eye drops
03/14/2007CN1927180A Anticancer slow release injection comprising tetrazole violet and potentiating agent thereof
03/14/2007CN1927179A Compound recipe anticancer slow release injection comprising tetrazole violet
03/14/2007CN1927178A Slow release injection loading both tetrazole violet and cytotoxic drug
03/14/2007CN1927176A Anticancer slow release comprising tetrazole violet and cytotoxic drug
03/14/2007CN1927175A Compound recipe anticancer slow release injection comprising tetrazole violet
03/14/2007CN1927174A Anticancer slow release injection loading tetrazole violet and potentiating agent thereof
03/14/2007CN1927173A Compound recipe anticancer slow release agent comprising tetrazole violet
03/14/2007CN1927172A Anticancer slow release agent comprising tetrazole violet and potentiating agent thereof
03/14/2007CN1927171A Anticancer slow release comprising tetrazole violet and cytotoxic drug
03/14/2007CN1927170A Anticancer slow release agent loading both newborn blood vessel and tetrazole violet
03/14/2007CN1927168A Implantation slow release medicine in eyes
03/14/2007CN1927137A Pre-transplant accommodated organs resistant to anti-donor immunity
03/14/2007CN1304572C Modified antisense nucleotides complementary to section of human Ha-Ras gene
03/14/2007CN1304567C Method and compositions useful for modulation of angiogenesis using tyrosine kinase SRC
03/14/2007CN1304415C Pyrane derivatives as both ACE- and NEP- inhibitors
03/14/2007CN1304389C Piperidine derivatives useful as CCR5 antagonists
03/14/2007CN1304054C Combination of slow released anticancer medication
03/14/2007CN1304053C Composition medicine for curing acute early-young granulocytic leukemia
03/14/2007CN1304052C Medicinal compositions for application to mucosa
03/14/2007CN1304051C PSGL-1 regulator
03/14/2007CN1304047C Use of long pentraxin PTX3 for treatment of diseases caused by altered activation of growth factor FGF-2
03/14/2007CN1304005C Combinations of receptor tyrosine kinase inhibitor with a1-acidic glycoprotein binding organic compound
03/14/2007CN1304000C Use of valsartan in preparing drug for treating lung cancer
03/14/2007CN1303953C Composition for acceleration of wound and burn healing and wound and burn healing dressing
03/13/2007US7189854 Reacting 4-(2-hydroxyethyl)piperazine and 2-((2-methyl,6-chloro-pyrimidin-4-yl)-amino),5-(2-chloro,6-methyl-phenyl)thiazole to obtain 2-((2-hydroxyethyl)piperazin-4-yl)-(2-methylpyrimidin-6,4-ylene)amino-),5-(2-chloro,6-methyl-phenyl)thiazole; antiarthritic,-tumor, -carcinogentic agents; immunology
03/13/2007US7189834 Oligoribonucleotides (ORNs) that are stress response factors from bacteria for use as immunostimulants in animals to withstand microbial infections and the lethality of endotoxic shock
03/13/2007US7189812 Comprises maternal protein (MATER) for treatment of infertility and reduced fertility; contraceptives
03/13/2007US7189808 Use of carboxy-terminal fragment of Ki-67 protein or of an active part, fragment or homologue thereof as compound that can be used for intracellular transfer and for introduction into and release by cells; antiinflammatory, anticancer agents
03/13/2007US7189761 Nitric oxide donor composition and method for treatment of anal disorders
03/13/2007US7189759 Compositions for the treatment of pigmentation disorders and methods for their manufacture
03/13/2007US7189755 Pyrrolidine melanocortin-specific compounds
03/13/2007US7189752 Anticancer agents
03/13/2007US7189749 Substituted phenoxyacetic acids
03/13/2007US7189719 Sodium channel blockers
03/13/2007US7189704 6-11 bicyclic ketolide derivatives
03/13/2007US7189703 Treatment and diagnosis of alzheimer's disease
03/13/2007US7189562 Mononuclear phagocytes in therapeutic drug delivery
03/13/2007US7189536 Which is incapable of reproduction within human cell lines; for treatment of human immunodeficency virus
03/13/2007US7189525 Human enzymes of the metalloprotease family
03/13/2007US7189523 Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a B-cell associated protein
03/13/2007US7189518 Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseases
03/13/2007US7189418 Method for extracting lipid mixture containing phospholipids comprising polyunsaturated fatty acids from viscera of fish, method for preserving viscera prior to extraction, and lipid mixture extracted thereby
03/13/2007US7189409 Porous carrier of ceramics or glass and pyrrolidone on the carrier for composites and bonding to carrier
03/13/2007CA2420895C Method for treating erectile dysfunction and increasing libido in men
03/13/2007CA2398182C Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
03/13/2007CA2355618C Polyol/oil suspensions for the sustained release of proteins
03/13/2007CA2274756C Methods and pharmaceutical compositions for inhibiting tumour cell growth
03/13/2007CA2267224C Vitronectin receptor antagonists
03/13/2007CA2266581C Polymers containing polysaccharides such as alginates or modified alginates
03/13/2007CA2219280C Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
03/13/2007CA2192209C Treatment of optic neuritis
03/08/2007WO2007027849A2 Multiribbon nanocellulose as a matrix for wound healing
03/08/2007WO2007027560A2 Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents
03/08/2007WO2007026969A1 Drug target protein and target gene, and screening method
03/08/2007WO2007026960A1 Use of mocs3 gene for therapeutic or diagnostic purposes
03/08/2007WO2007026928A1 Therapeutic agent for neuropathic pain
03/08/2007WO2007026630A1 Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid
03/08/2007WO2007026567A1 ANALGESIC AGENT COMPRISING p75NTR INHIBITOR AS ACTIVE INGREDIENT
03/08/2007WO2007026533A1 Soluble tablet containing nanosilicon particles and process for production thereof
03/08/2007WO2007026224A2 5-ht1b antagonist composition for depression, anxiety and cognition
03/08/2007WO2007026219A2 Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions
03/08/2007WO2007025554A1 Method for the generation of antigen-specific t-cells and uses thereof
03/08/2007WO2006125818A3 Oral pharmaceutical formulation for the prevention and/or the treatment of cardiovascular and inflammatory diseases
03/08/2007WO2006121968A3 Method for treatment of uterine fibroid tumors
03/08/2007WO2003047611A8 Ptp10d, tec and edtp involved in triglycerid-metabolism
03/08/2007WO2003020702A3 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
03/08/2007US20070054961 Factor
03/08/2007US20070054947 Pharmaceutical composition comprising valsartan
03/08/2007US20070054932 Inhibitors of ABC drug transporters at the blood-brain barrier
03/08/2007US20070054888 Novel substituted diamine derivatives useful as motilin agonists
03/08/2007US20070054878 Use of hyaluronic acid derivatives for inhibiting inflammatory arthritis
03/08/2007US20070054874 Methods for the selective treatment of tumors by calcium-mediated induction of apoptosis
03/08/2007US20070054861 Therapeutic uses of SMR1 peptides
03/08/2007US20070054312 Human transmembrane proteins
03/08/2007US20070053964 Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist
03/08/2007US20070053960 Multiribbon nanocellulose as a matrix for wound healing
03/08/2007US20070053902 Anti-alphabeta3 humanized monoclonal antibodies
03/08/2007US20070053888 Use of umbilical cord blood to treat individuals having a disease, disorder or condition
03/08/2007US20070053887 Method for production of neuroblasts
03/08/2007US20070053849 Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
03/08/2007US20070053845 Nanocell drug delivery system
03/08/2007US20070053838 Comprises therapeutically effective amounts of at least one chemotherapeutic agent along with the biotherapeutic endogenous pentapeptide Met-enkephalin (opioid growth factor); cancer
03/08/2007US20070053833 Hydrating a leukemia patient; parenterally administering a dose samarium ethylenediaminetetramethylenephosphonic acid (EDTMP); and melphalan, busulfan, and/or cyclophosphamiide; anticarcinogenic, antitumor, and antantiproliferative agents; autoimmune, infectious , metabolic or genetic disorders
03/08/2007DE19958198B4 Mit dem IGF-1 Rezeptor wechselwirkende Proteine (IIPs) With the IGF-1 receptor interacting proteins (IIPs)
03/08/2007DE102005042544A1 Beeinflussung des kardialen Fc-Rezeptors zur Behandlung der dilatativen Kardiomyopathie Influencing the cardiac Fc receptor for the treatment of dilated cardiomyopathy
03/08/2007CA2621037A1 Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents
03/08/2007CA2619445A1 Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid
03/08/2007CA2605228A1 Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level
03/07/2007EP1760087A1 Novel protein complex and use thereof
03/07/2007EP1759734A2 Aromatase inhibition to enhance assisted reproduction
03/07/2007EP1759718A1 Tissue closing preparation
03/07/2007EP1759710A1 Remedy or preventive for arthritis
03/07/2007EP1759704A2 Metal compounds, mixed or sulphated, as phosphate binders
03/07/2007EP1759701A2 Buproprion Metabolites and Methods of Their Synthesis and Use.
03/07/2007EP1759700A1 Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders